# SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

> **NCT04735042** · — · COMPLETED · sponsor: **University of Pisa** · enrollment: 60 (actual)

## Conditions studied

- Type 2 Diabetes
- Urinary Tract Infections

## Interventions

- **DRUG:** Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill
- **DRUG:** Empagliflozin or Dapagliflozin Pill

## Key facts

- **NCT ID:** NCT04735042
- **Lead sponsor:** University of Pisa
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-07
- **Primary completion:** 2021-10-07
- **Final completion:** 2022-04-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735042, "SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04735042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*